Date: 2017-02-01
Type of
information: Initiation of the trial
phase: 1b
Announcement: initiation of the trial
Company: Emergent BioSolutions (USA - MD)
Product: UV-4B
Action
mechanism: iminosugar. UV-4B is the lead dengue virus therapeutic candidate in Emergent’s iminosugar library. Iminosugars are small molecule therapeutics that target host glycosidase enzymes leading to reduced virus infectivity in multiple viruses such as dengue, Zika, SARS, and influenza. This novel host-based mechanism of action allows the potential for broad-spectrum application and a reduced probability of developing drug resistance.
Disease: dengue fever
Therapeutic
area: Infectious diseases
Country: USA
Trial
details:
Latest
news:
- • On February 1, 2017, Emergent BioSolutions announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company’s novel antiviral candidate being developed as a potential oral treatment for dengue viral infection. This study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016. Preclinical studies have shown that UV-4B is active in vitro against all four dengue virus subtypes and in vivo studies have shown improved survival even when dosing was delayed by up to 48 hours post-infection.
- This study is fully funded under development contract HHSN272201100030C with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health of the U.S. Department of Health and Human Services.
Is
general: Yes
